Pulsed Field Ablation for Ventricular Tachycardia: Exploring A New World-Pulsed Field Ablation for Ventricular Tachycardia: Exploring A New World

Video Transcription

Video Summary

In this HRS session, multiple speakers discuss the use of pulse field ablation (PFA) for ventricular tachycardia (VT), highlighting its benefits, challenges, and findings from recent studies. Dr. Andrea Sarkozy from the University Hospital of Brussels and Dr. Mohan Viswanathan from Stanford University co-chair the session. Dr. Arva Younis from Cleveland Clinic presents initial preclinical evidence that PFA can create deeper and larger lesions compared to radiofrequency (RF) ablation, suggesting improved outcomes for idiopathic VT substrates.<br /><br />Dr. Jacob Koruth from Mount Sinai Medical Center explores scar-based VT substrates, emphasizing the distinct advantage of PFA in creating effective lesions through scar tissue, which is hard to penetrate with RF. He also notes the potential for contact force to influence lesion depth significantly with focal catheters. Dr. Luigi Pannone shares clinical experiences from Brussels using the Sphere 9 (lattice-tip catheter) for VT ablation, reporting promising results and fast procedures with manageable complications.<br /><br />The session also includes insights into safe and effective PFA applications, like those in the coronary sinus for challenging substrate areas, and the potential for new catheters that balance lesion depth and safety. Overall, the speakers underscore that while PFA shows significant promise, particularly for complex VT and scarred tissue, more research is needed to optimize catheter design and application strategies. The discussions also touch on the potential for epicardial approaches and considerations for myocardial thinning post-ablation.

Keywords

Pulse Field Ablation

Ventricular Tachycardia

Radiofrequency Ablation

Idiopathic VT

Scar-based VT

Sphere 9 Catheter

Lesion Depth

Epicardial Approaches

Myocardial Thinning

Catheter Design